MetabolicFDA Approved

Teduglutide (Gattex)

Subcutaneous injection

Overview

Teduglutide is a recombinant analogue of human glucagon-like peptide-2 (GLP-2) comprising 33 amino acids with a single amino acid substitution that confers resistance to enzymatic degradation by dipeptidyl peptidase-4. This GLP-2 receptor agonist enhances intestinal epithelial barrier function, promotes mucosal growth, and increases mesenteric blood flow, thereby improving nutrient and fluid absorption.

Mechanism of Action

The therapeutic rationale centers on reducing dependence on parenteral nutrition in patients with short bowel syndrome by augmenting remnant bowel adaptive capacity..

Research Summary & Key Findings

Teduglutide received FDA approval in 2012 for adults with short bowel syndrome dependent on parenteral support, based on pivotal phase 3 trial data published in Gastroenterology (2011) demonstrating significant reductions in parenteral nutrition volume. Pediatric approval followed in 2019 after the phase 3 trial results were published in JPEN (2017), confirming efficacy and safety in children aged one year and older.

Clinical Status

FDA Approved

Teduglutide (Gattex) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers Teduglutide (Gattex) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Teduglutide (Gattex).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.